Business Wire

Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Congress and SynBioBeta Global Synthetic Biology Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, ...
TMCnet

Dyno Therapeutics Unveils Best-in-Class Dyno-bn8 AAV Vector for Muscle Gene Therapies, Achieving Therapeutic Delivery With Improved Safety Potential

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced Dyno-bn8, a novel adeno-associated virus ...
GEN - Genetic Engineering and Biotechnology News

Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner

The inaugural Genetic Agency Technology Conference (GATC) gathered a group of researchers and entrepreneurs to discuss the vision for AI-based genetic medicine.
Morningstar

Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy ...

Dyno’s AI-designed capsids improved therapeutic gene delivery to eye, muscle and CNS compared to commonly used AAV capsids, showcasing improved delivery efficiency, target-organ specificity and ...